skip to Main Content

Rucaparib Maintenance Shows Early Efficacy in Pancreatic Cancer

Rucaparib Maintenance Shows Early Efficacy in Pancreatic Cancer
Maintenance therapy with rucaparib (Rubraca) maintained disease control and was well tolerated in patients with platinum-sensitive, advanced BRCA1/2- or PALB2-mutant pancreatic cancer, according to preliminary interim findings of a single-arm, phase II trial presented at the 2019 AACR Annual Meeting.

Of 19 evaluable patients who were treated with the PARP inhibitor, results showed that the median progression-free survival (PFS) was 9.1 months at a median potential follow-up of 257 days, and the median overall survival was not reached at a median potential follow-up of 244 days. Read more . . . 


Back To Top